Loading clinical trials...
Loading clinical trials...
A Multi-country, Multi-center, Retrospective Chart Review to Describe the Use of Maribavir and Its Effectiveness in Patients With Post-Transplant Cytomegalovirus Infection/Disease
The main aim of this study is to check how effective the treatment with Maribavir has been to remove the CMV viruses from the blood of an adult person with CMV infection after a transplant. Other aims are to learn more about how maribavir is used in normal clinical routine, study the profiles of adults treated with maribavir, and what other treatments have been given, and describe healthcare resources used for CMV management. Only data already available in the medical records of the participants will be reviewed and collected during this study.
This study will include two main periods of retrospective data collection from medical charts: the pre-index period and the post-index period. The index date is defined as the date of initiation of maribavir dosing, as documented in the medical records. The pre-index period covers the time from the transplant date to the index event, while the post-index period starts at the index event and ends at the date of chart abstraction, death, or loss to follow-up, whichever comes first.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Medical University of Vienna Dept. of Nephrology and Dialysis
Vienna, Austria
Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark
Groupe Hospitalier Pellegrin - CHU BORDEAUX
Bordeaux, France
Department of Nephrology, University Hospital of Dijon
Dijon, France
Hopital Claude Huriez CHRU Lille
Lille, France
CHU Montpellier
Montpellier, France
CHU De Nice Hopital Pasteur 2
Nice, France
Hopital Saint-Louis AP-HP Pitor
Paris, France
APHP, Sorbonne University, Pitie Salpetriere Hospital
Paris, France
Necker-Enfants Malades Hospital
Paris, France
Start Date
October 14, 2024
Primary Completion Date
July 4, 2025
Completion Date
July 4, 2025
Last Updated
August 8, 2025
265
ACTUAL participants
No Intervention
OTHER
Lead Sponsor
Takeda
NCT06439342
NCT06793124
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03486834